For the Inventor, By the Inventor

Enter assignee name

Coral Gables, FL, United States of America

Stiefel Laboratories, Inc.

Calculating rank

USPTO Granted Patents = 34

% Expired Patents = 26.5

CIPO Patents = 2

EPO Patents = 4

Trademarks = 22

Forward Citations = 418

Loading Chart...

Loading Chart...

41 inventors (with patents filed for the assignee):

Werner K Stiefel (8 out of 8 patents)

Karl F Popp (5 out of 23 patents)

Kathleen L Clark (3 out of 3 patents)

4. Charles F Breunig (3 out of 3 patents)

5. Edward Richard Yuhas (2 out of 10 patents)

6. Joao Paulo Caetano (2 out of 2 patents)

7. Monica Alves Mariani De Oliveira (2 out of 2 patents)

8. Charles W Stiefel (2 out of 3 patents)

9. Debra Barrett (2 out of 2 patents)

10. Karin U Schallreuter (2 out of 2 patents)

11. John M Wood (2 out of 2 patents)

12. Henry Y Young (2 out of 2 patents)

13. Joanne M Fraser (1 out of 1 patent)

14. Keith Lorimer (1 out of 13 patents)

15. Jeffrey S Reynolds (1 out of 1 patent)

Core Competencies:

Anti-Pruritic Compositions

Skin Lightening

Acne Treatments

Sulfacetamide Formulations

Crystalline Antifungal Compounds

Dietary Supplements

Psoriasis Treatments

Therapeutic Compositions

Emollient Formulations

Tazarotene Derivatives

Foamable Compositions

Depigmentation Disorders

34 patents: Sort by Forward Citations

1. 10118055 - Topical anti-pruritic compositions and methods of action of same (2018-11-06),

2. 9364424 - Topical cosmetic skin lightening compositions and methods of use thereof (2016-06-14),

3. 9241893 - Topical cosmetic skin lightening compositions and methods of use thereof (2016-01-26),

4. 9107844 - Topical skin treating compositions (2015-08-18),

5. 9062037 - Tazarotene derivatives (2015-06-23),

6. 8399495 - Talarazole metabolites (2013-03-19),

7. 8188124 - Talarazole metabolites (2012-05-29),

8. 8071133 - Oral dosage forms of water insoluble drugs and methods of making the same (2011-12-06),

9. 7879867 - Crystalline antifungal compounds (2011-02-01),

10. 7829107 - Foamable pharmaceutical compositions and methods for treating a disorder (2010-11-09),

11. D623519 - Jar venting disc (2010-09-14),

12. 7357938 - Sulfacetamide formulations for treatment of rosacea (2008-04-15),

13. 7186416 - Foamable pharmaceutical compositions and methods for treating a disorder (2007-03-06),

14. 7022332 - Sulfacetamide formulations for treatment of rosacea (2006-04-04),

15. 6699464 - Compositions for treatment of hyperpigmentation and methods for making and using such compositions (2004-03-02),

Company Overview

Stiefel Laboratories, Inc. is a prominent pharmaceutical company specializing in dermatology. Based in Coral Gables, Florida, the organization focuses on developing and manufacturing a wide range of products aimed at treating various skin conditions. With a commitment to innovation, Stiefel leverages advanced research and technology to enhance the efficacy and safety of its offerings. The company serves a global market, providing solutions that address both common and complex dermatological needs.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

34 Patents

#2 in Coral Gables, FL

#245 in Florida

#10,028 in US

#19,664 in the World

Coral Gables, FL, United States of America

Stiefel Laboratories, Inc.

Forward Citations = 418

41 inventors:

Werner K Stiefel (8 out of 8 patents)

Karl F Popp (5 out of 23 patents)

Kathleen L Clark (3 out of 3 patents)

4. Charles F Breunig (3 out of 3 patents)

5. Edward Richard Yuhas (2 out of 10 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Stiefel Laboratories, Inc.. Retrieved from https://idiyas.com/company/stiefel-laboratories

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…